Arcus Biosciences Announces New Employment Inducement Grants
03 Dezembro 2024 - 6:35PM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global
biopharmaceutical company focused on developing differentiated
molecules and combination therapies for patients with cancer, today
announced that the Compensation Committee of the Company’s Board of
Directors granted three new employees options to purchase a total
of 10,000 shares of the Company’s common stock at an exercise price
per share of $14.56, which was the closing price on November 25,
2024, and restricted stock units to acquire a total of 5,000 shares
of the Company’s common stock. The equity awards were granted
pursuant to the Company’s 2020 Inducement Plan, which was approved
by the Company’s Board of Directors in January 2020 pursuant to the
“inducement exception” under NYSE Listed Company Manual Rule
303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for people with cancer. In partnership with industry
collaborators, patients and physicians around the world, Arcus is
expediting the development of first- or best-in-class medicines
against well-characterized biological targets and pathways and
studying novel, biology-driven combinations that have the potential
to help people with cancer live longer. Founded in 2015, the
company has expedited the development of multiple investigational
medicines into clinical studies, including new combination
approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b
receptor, CD39 and AXL. For more information about Arcus
Biosciences’ clinical and preclinical programs, please visit
www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241203184348/en/
Investor Inquiries: Pia
Eaves VP of Investor Relations & Strategy (617) 459-2006
peaves@arcusbio.com
Media Inquiries: Holli Kolkey VP of Corporate
Communications (650) 922-1269 hkolkey@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
